Le Lézard
Classified in: Health, Science and technology
Subject: CCA

Syra Health To Discuss Fourth Quarter and Fiscal Year 2023 Financial Results


Conference call will be held on Monday, March 25 at 9:00 a.m. ET

CARMEL, Ind., March 19, 2024 /PRNewswire/ -- Syra Health Corp. (NASDAQ: SYRA), ("Syra Health" or the "Company") a healthcare consulting company with a mission to improve healthcare by providing innovative services and technology solutions, announced today that it will report financial results for its fourth quarter and fiscal year 2023 ended December 31, 2023, on Monday, March 25, 2024, before the market opens. The Company has scheduled a conference call for that same day, March 25, 2024, at 9:00 a.m. ET, to review the results.

Interested parties can access the conference call via Internet webcast, which is available in the Investors section of the Company's website at https://ir.syrahealth.com/presentations/q4-and-full-year-2023-earnings-call.

Investors who would like to submit a question to be addressed on the call should email the question to [email protected].

A webcast replay will be available in the Investors section of the Company's website at https://ir.syrahealth.com/presentations/q4-and-full-year-2023-earnings-call.

ABOUT SYRA HEALTH

Syra Health is a healthcare technology company addressing some of healthcare's most significant challenges in areas such as behavioral and mental healthdigital health, and population health, by providing innovative services and technology solutions. Syra Health's products and services are centered on prevention, improved access, and affordable care. Syra Health supplies its solutions to payers, providers, life sciences organizations, academic institutions, and government. For more information, please visit www.syrahealth.com.

For more information, please contact:

For Media Inquiries:
Christine Drury
Communications and Marketing Director
Syra Health
463-345-5180
[email protected]

For Investor Inquiries:
Ben Shamsian
Vice President
Lytham Partners, LLC
646-829-9701
[email protected]

SOURCE Syra Health


These press releases may also interest you

at 00:05
As May marks Preeclampsia Awareness Month, leading maternal health experts, preeclampsia survivors and industry leaders have come together on a new campaign, "Preeclampsia Prevention is Possible." The campaign elevates awareness of a major paradigm...

30 avr 2024
The report titled "Clinical Trial Analytics Services Market by Services (Clinical Data Analytics, Clinical Trial Data Management, Clinical Trial Planning & Monitoring), Component (Data Management & Integrity Services, Data Visualization &...

30 avr 2024
Jacobio Pharma (1167.HK) announced that the data from the Phase II registrational study of the KRAS G12C inhibitor glecirasib were offically reported at the April ASCO Plenary Series, which was held online. Prof. Yuankai Shi, chief physician of...

30 avr 2024
Waverley Pharma Inc. ("Waverley Pharma" or the "Company") , a Canadian pharmaceutical company, is announcing a business update. As mentioned in the previous business update dated August 2, 2023, opportunities Waverley Pharma envisioned of marketing...

30 avr 2024
Feeding Matters is proud to celebrate the 6th annual PFD Awareness Month, which is recognized around the globe. This designation, initiated by Feeding...

30 avr 2024
Korea Ginseng Corp. US (KGCUS) aka JungKwanJang held a dedicated international seminar session on "Korean Ginseng: Safety, Efficacy And Neuroprotective Insights'' at the International Conference on the Science of Botanicals (ICSB) hosted by the...



News published on and distributed by: